A word from the CEO
The intense period in Xintela operations has continued and positively so. Previously, we reported on the good progress of both our regenerative medicine and cancer projects, which continue to develop quickly. We are currently focusing on starting stem cell production according to Good Manufacturing Practice (GMP), as well as obtaining regulatory approval for a clinical equine study.
In this newsletter, Caroline Ehrencrona, one of our key personnel and responsible for liaising with regulatory authorities and planning our clinical development, discusses the coming clinical equine study and how this differs from the preclinical study that we conducted last year at Cornell University.
We also continue to present video interviews in this newsletter. The current video, conducted and published by Biostock, is an interview with Marcus Keep, Doctor and Associate Professor of Neurosurgery working in the USA. He describes glioblastoma and the treatments available today for people affected with this brain tumour and what distinguishes Xintela’s treatment concept for this type of cancer.
Last, but not least, we are very pleased with the results of the recent warrant program and discuss this in more detail in this newsletter.
Best wishes,
CEO Evy Lundgren-Åkerlund
Xintela AB
